Market entry of biosimilar low-molecular-weight heparins in Europe: Opportunities and challenges

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 3, 2013, Pages 250-257

  Simoens, Steven ^a   Huys, Isabelle ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

biosimilar; low molecular weight heparin; market entry

Indexed keywords

BEMIPARIN; CERTOPARIN; DALTEPARIN; ENOXAPARIN; FRADOXIL; GENERIC DRUG; LOW MOLECULAR WEIGHT HEPARIN; MONOEMBOLEX; NADROPARIN; PARNAPARIN; REVIPARIN; TINZAPARIN; UNCLASSIFIED DRUG; ZIBOR;

ARTICLE; CLINICAL STUDY; DRUG CONTAMINATION; DRUG CONTROL; DRUG COST; DRUG DOSE; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; EUROPE; EXERCISE; HUMAN; IMMUNOGENICITY; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; RISK MANAGEMENT;

ANIMALS; BIOSIMILAR PHARMACEUTICALS; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; EUROPE; EUROPEAN UNION; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS;

EID: 84884211461     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1328970     Document Type: Article

References (47)

1. Gray E., Mulloy B. Biosimilar low molecular weight heparin products. J Thromb Haemost: 2009; 7 7 1218 1221
2. Clark C. Heparin: generic or biosimilar? Hospital Pharmacy Europe: 2011; 56 43 44
3. Chu R., Pugatch M. Biogenerics or biosimilars? Discussing the present, considering the future. Available at: http://www.stockholm-network.org/ downloads/publications/Biosimilars-FINAL.pdf. Accessed October 5, 2011
4. European Commission Directive 2004/27/EC of the European Parliament and of the Council of 31st March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union: 2004; 34 57
5. McCamish M., Woollett G. Worldwide experience with biosimilar development. MAbs: 2011; 3 2 209 217
6. European Medicines Agency Guideline on similar biological medicinal products. London, England: European Medicines Agency; 2006a. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003517.pdf. Accessed October 28, 2011
7. European Medicines Agency Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London, England: European Medicines Agency; 2003. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003963.pdf. Accessed October 28, 2011
8. European Medicines Agency Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London, England: European Medicines Agency; 2005a. Available at: http://www.triskel.com/ 2%20Guideline%20biotech%20derived%20proteins.pdf. Accessed October 26, 2011
9. European Medicines Agency Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London, England: European Medicines Agency; 2005b. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003953.pdf. Accessed October 24, 2011
10. European Medicines Agency Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. London, England: European Medicines Agency; 2006b. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003946.pdf. Accessed August 5, 2011
11. European Medicines Agency Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight-heparins. London, England: European Medicines Agency; 2007. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003927.pdf. Accessed October 28, 2011
12. European Medicines Agency Concept paper on the revision of the guideline on nonclinical and clinical development of similar biological medicinal products containing low-molecular-weight heparins. London, England: European Medicines Agency; 2011a. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2011/07/WC500109588.pdf. Accessed October 28, 2011
13. European Medicines Agency Reflection paper on the use of starting materials and intermediates collected from different sources in the manufacturing of biological medicinal products (Draft paper). London, England: European Medicines Agency; 2012. Available at: http://www.ema.europa.eu/docs/en- GB/document-library/Scientific-guideline/2012/02/WC500123445.pdf. Accessed March 9, 2012
14. Auguste C., Dereux S., Martinez C., Anger P. New developments in quantitative polymerase chain reaction applied to control the quality of heparins. Anal Bioanal Chem: 2011; 399 2 747 755
15. Huang Q., Xu T., Wang G-Y., et al. Species-specific identification of ruminant components contaminating industrial crude porcine heparin using real-time fluorescent qualitative and quantitative PCR. Anal Bioanal Chem: 2012; 402 4 1625 1634 10.1007/s00216-011-5590-2
16. Harenberg J., Kakkar A., Bergqvist D., et al. Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost: 2009; 7 7 1222 1225
17. European Medicines Agency Concept paper on the revision of the guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: non-clinical and clinical issues. London, England: European Medicines Agency; 2011b. Available at: http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2011/10/WC500115611.pdf. Accessed October 28, 2011
18. European Medicines Agency Guideline on clinical investigation of the pharmacokinetics of therapeutic proteins. London, England: European Medicines Agency; 2005c. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003031.pdf. Accessed October 28, 2011
19. Drouet L. Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit? Target Oncol: 2012; 7 01 S35 S42
20. Houiste C., Auguste C., Macrez C., Dereux S., Derouet A., Anger P. Quantitative PCR and disaccharide profiling to characterize the animal origin of low-molecular-weight heparins. Clin Appl Thromb Hemost: 2009; 15 1 50 58
21. Walenga J. M., Hoppensteadt D., Cunanan J., et al. Immunogenicity of low molecular weight heparins and their biosimilars. J Thromb Haemost: 2009; 7 02 136
22. BioGeneriX Follow-on Biologics Forum: the delivery of regulatory, legal and business strategies balanced by scientific debates. Presented at: Follow-on Biologics Forum; April 27-29, 2005; Washington, DC
23. Grabowski H., Cockburn I., Long G. The market for follow-on biologics: how will it evolve? Health Aff (Millwood): 2006; 25 5 1291 1301 (Pubitemid 44497628)
24. Holmes D. R. Jr, Becker J. A., Granger C. B., Limacher M. C., Page R. L. II, Sila C. ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. Circulation: 2011; 124 11 1290 1310
25. Yoshida W. Studies on biosimilar medications. Jornal Vascular Brasileiro: 2010; 9 141 144
26. Kishimoto T. K., Viswanathan K., Ganguly T., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med: 2008; 358 23 2457 2467 (Pubitemid 351793019)
27. Kalodiki E., Fareed J. New and generic anticoagulants and biosimilars: safety considerations. Clin Appl Thromb Hemost: 2011; 17 2 136 139
28. Research in China Export Price Trend of Heparin Products in China, 2008-Jul. 2011 (USD/kg). Research in China; 2011. Available at: http://www.researchinchina.com/news/NewsContent.aspx?id=23343. Accessed July 10, 2012
29. Health I. MS. Health care data. London, England IMS Health: 2011
30. Zuniga L., Calvo B. Biosimilars-the way forward. Hospital Pharmacy Europe: 2010; 50 33 34
31. Mellstedt H. The future of biosimilars. Hospital Pharmacy Europe: 2010; 49 33 34
32. Long M., Trout J., Akpinar P. Biosimilars: HGH to TNFS, how will payers respond? Paper presented at: ISPOR 12th Annual European Congress; October 28, 2009; Paris, France
33. European Generic Medicines Association Biosimilars handbook. Brussels, Belgium European Generic Medicines Association: 2011; 1 54
34. Malhotra H. Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation. Biologicals: 2011; 39 5 321 324
35. Jackson C. M. Biosimilars: considerations with low molecular weight heparins. Clin Adv Hematol Oncol: 2010; 8 3 163 167
36. Marcus P., Tapson V. F. Background, scope of the problem, and therapeutic options. Chest Physician; September 2008. Available at: http://www.chestnet. org/downloads/about/chestPhysician/Sept08supplement.pdf. Accessed July 9, 2012
37. Liefner M. Biosimilars' price dynamic in Europe. London, England Office of Health Economics: 2010
38. Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res: 2011; 3 29 36
39. National Institute for Health and Clinical Excellence Human growth hormone (somatropin) for the treatment of growth failure in children (review of NICE technology appraisal guidance 42). London, England: National Institute for Health and Clinical Excellence; 2010. Available at: http://guidance.nice.org.uk/ TA188. Accessed October 28, 2011
40. Scottish Medicines Consortium Ratiograstim. Glasgow, Scotland: Scottish Medicines Consortium; 2009. Available at: http://www.scottishmedicines.org.uk/ files/filgrastim-Ratiograstim-FINAL-Oct-2009-Revised-031109.doc-for-website.pdf. Accessed October 8, 2011
41. Scottish Medicines Consortium Epoetin zeta. Glasgow, Scotland: Scottish Medicines Consortium; 2010. Available at: http://www.scottishmedicines.org.uk/ smc/6094.html. Accessed October 8, 2011
42. Fareed J. Differentiation among the low-molecular-weight heparins. Chest Physician; September 2008. Available at: http://www.chestnet.org/downloads/ about/chestPhysician/Sept08supplement.pdf. Accessed July 9, 2012
43. Fareed J., Leong W. L., Hoppensteadt D. A., et al. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost: 2004; 30 6 703 713 (Pubitemid 40041606)
44. European Medicines Agency Questions and Answers on biosimilar medicines. London, England: European Medicines Agency; 2008. Available at: http://www.emea.europa.eu/docs/en-GB/document-library/Medicine-QA/2009/12/ WC500020062.pdf. Accessed October 4, 2011
45. Hodgson J. WHO guidelines presage US biosimilars legislation? Nat Biotechnol: 2009; 27 11 963 965
46. Moran N. Fractured European market undermines biosimilar launches. Nat Biotechnol: 2008; 26 1 5 6
47. Federal Trade Commission Emerging health care issues: follow-on biologic drug competition. Federal Trade Commission; 2009. Available at: http://www.ftc.gov/os/2009/06/P083901biologicsreport.pdf. Accessed October 6, 2011